222 related articles for article (PubMed ID: 16997178)
21. New therapeutic strategies in acute lymphoblastic leukemia.
Jeha S
Semin Hematol; 2009 Jan; 46(1):76-88. PubMed ID: 19100370
[TBL] [Abstract][Full Text] [Related]
22. [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation].
Abe T; Kitajima T; Honma K; Kurasaki T; Okazuka K; Shibasaki Y; Momoi A; Kuroha T; Masuko M; Yagisawa K; Furukawa T; Toba K; Aizawa Y
Rinsho Ketsueki; 2008 Nov; 49(11):1556-61. PubMed ID: 19047788
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
24. Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome.
Asgarian Omran H; Shabani M; Shahrestani T; Sarafnejad A; Khoshnoodi J; Vossough P; Faranoush M; Sharifian RA; Jeddi-Tehrani M; Rabbani H; Shokri F
Iran J Immunol; 2007 Mar; 4(1):15-25. PubMed ID: 17652839
[TBL] [Abstract][Full Text] [Related]
25. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
Amadori S; Stasi R
Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
[TBL] [Abstract][Full Text] [Related]
26. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
27. Emerging biological therapies to treat acute lymphoblastic leukemia.
Huguet F; Tavitian S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
[TBL] [Abstract][Full Text] [Related]
28. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
Willemze R; Labar B
Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
30. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
31. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia.
Pui CH; Jeha S
Nat Rev Drug Discov; 2007 Feb; 6(2):149-65. PubMed ID: 17268486
[TBL] [Abstract][Full Text] [Related]
32. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
Gisselbrecht C
Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
[TBL] [Abstract][Full Text] [Related]
33. [Acute lymphoblastic leukemia (ALL)].
Imai K; Akiyama H
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2180-4. PubMed ID: 18079617
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody therapy in acute myeloid leukemia.
Feldman EJ
Curr Hematol Rep; 2003 Jan; 2(1):73-7. PubMed ID: 12901157
[TBL] [Abstract][Full Text] [Related]
35. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
36. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
37. Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92.
Calaminus G; Hense B; Laws HJ; Groeger M; MacKenzie CR; Göbel U
Klin Padiatr; 2007; 219(6):355-60. PubMed ID: 18050047
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy.
Jaime-Pérez JC; Rodríguez-Romo LN; González-Llano O; Chapa-Rodríguez A; Gómez-Almaguer D
Br J Haematol; 2009 Mar; 144(5):794-5. PubMed ID: 19036096
[No Abstract] [Full Text] [Related]
39. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.
Chevallier P; Robillard N; Houille G; Ayari S; Guillaume T; Delaunay J; Harousseau JL; Avet-Loiseau H; Mohty M; Garand R
Leukemia; 2009 Apr; 23(4):806-7. PubMed ID: 18971949
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]